VJOncology is committed to improving our service to you

ESMO 2019 | Erdafitinib for bladder cancer: more to come following FDA approval

VJOncology is committed to improving our service to you

Arlene Siefker-Radtke

Erdafitinib, an FGFR3 inhibitor, was approved by the FDA in April 2019 for the treatment of FGFR3+ metastatic urothelial carcinoma patients. Here Arlene Siefker-Radtke, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses what’s next for this agent, including its future in Europe and the THOR trial (NCT03390504).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter